Phase I oncology trials: Why the therapeutic misconception will not go away

Journal of Medical Ethics

Volumn 32, Issue 5, 2006, Pages 252-255

  Glannon, W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RESEARCH; COGNITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EMOTION; HEALTH BELIEF; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT ATTITUDE; PATIENT PARTICIPATION; PHYSICIAN ATTITUDE; PSYCHOLOGICAL ASPECT; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DECISION MAKING; EMOTIONS; HUMANS; INFORMED CONSENT; NEOPLASMS; PATIENT EDUCATION; PATIENT SELECTION; RESEARCHER-SUBJECT RELATIONS;

EID: 33646397584     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2005.015685     Document Type: Editorial

References (14)

1. Appelbaum PS, Roth L, Lidz CW. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982;5:319-29.
2. Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 2004;26:1-8.
3. Miller F, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep 2003;33:19-28.
4. Appelbaum PS. Clarifying the ethics of clinical research: a path toward avoiding the therapeutic misconception. Am J Bioeth 2002;2:22-3.
5. Horng S, Emanuel E, Wilfond B. Description of benefits and risks in consent forms for phase I clinical trials. New Engl J Med 2002;347:1234-40.
6. King N. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 2000;28:332-43.
7. Daugherty C, Ratain MJ, Grochowski S, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995;9:1062-72.
8. Miller M. Phase I cancer trials: a collusion of misunderstanding. Hastings Cent Rep. 2000;30: 34-42, at 40).
9. Miller FG, Rosenstein DL. The therapeutic orientation to clinical trials. New Engl J Med 2003;348:1383-6.
10. Pentz RD, Flamm AL, Sugarman J, et al. Study of the media's potential influence on prospective research participants' understanding of and motivation for participation in a high-profile phase I trial. J Clin Oncol 2002;20:3785-91.
11. Flory J, Emanuel E. Interventions to improve research participants' understanding of informed consent to research: a systemic review. JAMA 2004;292:1593-601.
12. Dunn LB, Gordon NE. Improving informed consent and enhancing recruitment for research by understanding. JAMA 2005;293:609-12.
13. Grady C. Money for research participation: does it jeopardize informed consent? Am J Bioeth 2001;1:40-4.
14. Grady C. Payment of clinical research subjects. J Clin Invest 2005;115:1681-7.